Literature DB >> 30128323

Mapt deletion fails to rescue premature lethality in two models of sodium channel epilepsy.

Chunling Chen1, Jerrah K Holth2,3,4, Rosie Bunton-Stasyshyn5, Charles K Anumonwo1, Miriam H Meisler5, Jeffrey L Noebels2,3, Lori L Isom1.   

Abstract

Deletion of Mapt, encoding the microtubule-binding protein Tau, prevents disease in multiple genetic models of hyperexcitability. To investigate whether the effect of Tau depletion is generalizable across multiple sodium channel gene-linked models of epilepsy, we examined the Scn1b-/- mouse model of Dravet syndrome, and the Scn8aN1768D/+ model of Early Infantile Epileptic Encephalopathy. Both models display severe seizures and early mortality. We found no prolongation of survival between Scn1b-/-,Mapt+/+ , Scn1b-/-,Mapt+/-, or Scn1b-/-,Mapt-/- mice or between Scn8aN1768D/+,Mapt+/+ , Scn8aN1768D/+,Mapt+/- , or Scn8aN1768D/+,Mapt-/- mice. Thus, the effect of Mapt deletion on mortality in epileptic encephalopathy models is gene specific and provides further mechanistic insight.

Entities:  

Year:  2018        PMID: 30128323      PMCID: PMC6093838          DOI: 10.1002/acn3.599

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


Introduction

Deletion of Mapt, encoding the microtubule‐binding protein Tau, has been shown to attenuate hyperexcitability and prevent disease in a mouse model of Alzheimer's Disease with epilepsy,1 the Kcna1 mouse model of temporal lobe epilepsy,2 the Scn1a mouse model of Dravet syndrome (DS),3 and bang‐sensitive Drosophila mutants.2 As a result of this work, Tau has been proposed to be a viable target for the development of novel anti‐epileptic therapeutic agents. To investigate whether the effect of Tau depletion is generalizable across additional gene models of epilepsy with premature lethality, we conducted a similar experiment using two different models of sodium channel gene‐linked epileptic encephalopathy: the Scn1b mouse model of DS 4 and the Scn8a model of Early Infantile Epileptic Encephalopathy (EIEE13).5 Scn1b encodes the β1 and β1B subunits of voltage‐gated sodium channels.6 Homozygous Scn1b mice are underweight, have cardiac defects, develop severe seizures at approximately postnatal day (P) 10, and 100% die by approximately P21. SCN1B is the only known genetic link to DS that is due to recessive inheritance.7, 8 The limited number of reported SCN1B‐linked DS cases show seizure onset in the first months of life, dramatic cognitive and motor delays, microcephaly, generalized wasting, severe kyphoscoliosis, central hypotonia, and spastic quadriplegia.7, 8 SCN8A encodes Nav1.6, a pore‐forming α subunit of the voltage‐gated sodium channel. Heterozygous missense mutations of SCN8A have been identified in more than 150 individuals with SCN8AEIEE13 many of which exhibit gain‐of‐function features.9 A mouse model expressing the patient mutation p.Asn1758Asp (N1768D) exhibits seizure onset at 2–5 months of age.5, 10 Death is usually observed within 1 week of seizure onset.11 Since SCN1B‐linked DS and SCN8A‐linked EIEE13 are both resistant to multiple anti‐epileptic drugs, there is a major need for the development of novel therapeutics for these devastating epilepsy syndromes.

Methods

Animals

All procedures were performed in accordance with the guidelines of the National Institutes of Health, as approved by the Animal Care and Use Committee of the University of Michigan and Baylor College of Medicine. Scn1b mice, congenic for over 20 generations (N > 20) on the C57Bl/6J background, were generated as described.4 Scn1b mice were crossed with Mapt mice (JAX stock #007251,B6.129X1‐Mapt /J) 12 to generate Scn1b ,Mapt mice, which were then bred to generate Scn1b ,Mapt Scn1b ,Mapt , and Scn1b ,Mapt mice for analysis. Scn8a mice 13 were backcrossed to strain C57BL/6J for six generations (N6) and crossed with C57BL/6J.Mapt mice. F2 mice with genotypes Scn8a ,Mapt , Scn8a ,Mapt , and Scn8a ,Mapt were used for analysis of survival. Additional Scn8a ,Mapt mice were obtained by crossing F1 mice with Mapt mice. Additional Scn8a ,Mapt were collected from generations N6 to N9 of the backcross to strain C57BL/6J. Male and female mice were used for all experiments. Mouse survival was monitored twice daily by individuals blinded to genotype. For the Scn1b mice, half of the animals were bred and analyzed at the University of Michigan and half at Baylor College of Medicine. There were no differences in the results and thus the data were pooled. PCR analysis of mouse tail DNA: DNA was prepared from mouse tail biopsies at P 10‐14 using standard methods.4

For Scn1b,Mapt mice

Two sets of primers were used in genotyping: Mapt primers: Mapt forward 5′‐GCC AGA GGC CAC TTG TGT AG‐3′; reverse 5′‐ATT CAA CCC CCT CGA ATT TT‐3′; Mapt : forward 5′ AAT GGA AGA CCA TGC TGG AG 3′; reverse 5′‐ATT CAA CCC CCT CGA ATT TT‐3′. Scn1b primers: Scn1b : forward 5′‐ AGA GAG AAT GGA GAA TCA AGC CAT AG‐3′; reverse 5′‐GCT ACT TCC ATT TGT CAC GTC CTG CAC‐3′; Scn1b : forward 5′‐CTT CTT TGA TCC CTC ACT GTC CG ‐3′; reverse 5′‐AGG TGG ATC TTC TTG ACG ACG CTG‐3′. The two primer sets were mixed and used together in a single PCR performed according to the following protocol: an initial denaturation step at 95°C for 2 min, followed by 30–35 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and elongation at 71°C for 1 min 20 sec, and a final step at 72°C for 7 min. The results were analyzed by agarose gel electrophoresis. For Scn8a , Mapt mice, PCR primers 5′‐TACTGCTGCCAATCCTGAAC‐3′ and 5′‐CAAAGTCGGCCAGCTTACA‐3′ were used to amplify a 306 bp product. An initial denaturation at 95°C for 2 min was followed by 35 cycles of 95°C for 45 sec, 60°C for 30 sec, 72°C for 40 sec. The reaction was then digested with HincII restriction enzyme. The amplicon is resistant to HincII when amplified from the WT allele. When amplified from the mutant allele the presence of a HincII RE site results in digestion to a 146 bp and a 160 bp fragment. Genotyping of the Mapt allele was based on the protocol published on the Jackson Laboratory website (stock number 007251). Primers 5′‐ AATGGAAGACCATGCTGGAG‐3′, 5′‐ATTCAACCCCCTCGAATTTT‐3′ and 5′‐GCCAGAGGCCACTTGTGTAG‐3′ were used in a touchdown PCR. After initial denaturation at 95°C for 2 min, 10 cycles of 95°C for 30 sec, 65°C (decreasing by 0.5°C per cycle) for 30 sec, 72°C 30 sec, was followed by 28 cycles of 95°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec. Amplification of the WT allele results in a 269 bp product, whereas the Mapt allele gives a 190 bp product.

Statistical analysis

Mouse survival was analyzed by Kaplan–Meier Log Rank (Mantel–Cox).

Results

In contrast to Kcna1 and Scn1a mice, Mapt deletion had no observable effects on survival of Scn1b DS mice. Scn1b ,Mapt , Scn1b ,Mapt , and Scn1b , Mapt mice have overlapping survival curves (Fig. 1). Although affected mice were too young and too small for electroencephalographic monitoring prior to their death in the third postnatal week, all three groups of animals showed similar and clearly visible behavioral seizures up until death. In addition, the time of death was not significantly different between genotypes.
Figure 1

Mapt deletion does not affect survival of Scn1b mice. Kaplan–Meier analysis shows that Mapt deletion does not alter survival in Scn1b mice (Scn1b , Mapt : n = 11;Scn1b , Mapt : n = 26; Scn1b , Mapt : n = 11; Kaplan–Meier log rank). χ 2 = 1.063, P > 0.05. Log rank (Mantel–Cox) Chi square was calculated in GraphPad Prism assuming 2 degrees of freedom.

Mapt deletion does not affect survival of Scn1b mice. Kaplan–Meier analysis shows that Mapt deletion does not alter survival in Scn1b mice (Scn1b , Mapt : n = 11;Scn1b , Mapt : n = 26; Scn1b , Mapt : n = 11; Kaplan–Meier log rank). χ 2 = 1.063, P > 0.05. Log rank (Mantel–Cox) Chi square was calculated in GraphPad Prism assuming 2 degrees of freedom. Deletion of Mapt alleles also had no effect on the survival of Scn8a mice. Comparison of survival during a 10‐month observation period did not detect any difference between Scn8a mutant mice with the compound genotypes of Mapt , Mapt , and Mapt (Fig. 2).
Figure 2

Mapt deletion does not affect survival of Scn8a EIEE13 mice. The survival of Scn8a mice was unaffected by their Mapt genotype (Scn8a ,Mapt : n = 217; Scn8a ,Mapt : n = 54; Scn8a ,Mapt : n = 36; Kaplan–Meier log rank). χ 2 = 5.968, P > 0.05. Log rank (Mantel–Cox) Chi square was calculated in GraphPad Prism assuming 2 degrees of freedom.

Mapt deletion does not affect survival of Scn8a EIEE13 mice. The survival of Scn8a mice was unaffected by their Mapt genotype (Scn8a ,Mapt : n = 217; Scn8a ,Mapt : n = 54; Scn8a ,Mapt : n = 36; Kaplan–Meier log rank). χ 2 = 5.968, P > 0.05. Log rank (Mantel–Cox) Chi square was calculated in GraphPad Prism assuming 2 degrees of freedom.

Discussion

We report that the effects of Mapt deletion on genetic models of neural hyperexcitability are not uniform across all mouse models of epileptic ion channelopathy. Mice bearing the null mutation in Scn1b, a regulatory subunit of voltage‐gated neuronal and cardiac sodium channels, show epilepsy even in the absence of Tau protein, and loss of Tau does not prevent or delay premature lethality in this model. This is likely explained by the increased molecular complexity of Scn1b interactions with ion channel pore‐forming subunits. The mouse phenotype of SCN1B‐linked DS 4, 8 is more severe than models of SCN1A‐linked DS,14, 15 and may involve more subclasses of neurons and brain regions. β1/β1B subunits associate with and modulate the voltage‐gating properties of all sodium channel and some potassium channel α subunits.6 β1 and β1B are multifunctional, with nonconducting functions resembling those of immunoglobulin superfamily cell adhesion molecules.6 In addition to brain, Scn1b is expressed in heart, where it contributes to the regulation of cardiomyocyte excitability and excitation‐contraction coupling.16, 17 SCN1B mutations are linked to cardiac arrhythmia in humans and Scn1b mice have prolonged QT and RR intervals on the ECG.18 Scn1b is also expressed in pancreatic beta cells. Scn1b mice display a metabolic hypoglycemic phenotype due to abnormal insulin and glucagon release, likely contributing to failure to thrive and early neurologic hypofunction.19 Thus, SCN1B‐linked mortality may relate to combined downstream excitability disturbances in brain, heart, and neuroendocrine cells, not all of which can be rescued by loss of Tau, and the human disease may be more challenging in terms of therapeutic development. SCN8A gain‐of‐function mutations are associated with EIEE13, with onset ranging from prenatal life to 1 year of age. The functional effects of patient mutations in this pore‐forming subunit include premature channel opening and delayed channel inactivation.9 Elevated neuronal firing rates have been observed in hippocampal20 and cortical21 neurons from mice carrying the patient mutation SCN8AN1768D, which is located in the last transmembrane segment of the channel. Nav1.6 is concentrated at the axon initial segment (AIS), where it mediates action potential initiation in neurons throughout the CNS and PNS. The lack of effect of Mapt deletion on survival of mice with the N1768D mutation suggests that Tau may not be involved in the mechanism of Nav1.6 localization to the AIS. SCN8A is also expressed at low abundance in cardiac myocytes, which exhibit arrhythmic contractions and altered calcium handling in Scn8a mice.22 The role of cardiac arrhythmia in premature lethality of this mouse model remains unclear. At the cellular level, the effects of gain‐of‐function mutations of SCN8A are quite distinct from the loss‐of‐function mutations of SCN1A responsible for DS. How this difference in mechanism leads to divergent responses to Mapt deletion is a question for the future. The mechanism of sudden unexpected death in epilepsy (SUDEP) in epileptic encephalopathy is not known, although spreading depolarization to the brainstem, respiratory compromise, autonomic dysfunction, and cardiac arrhythmias have been implicated.22, 23, 24, 25, 26, 27 Mapt deletion, which has been shown to prolong life in the Kv1.1 null model of SUDEP, also restores the normal brainstem threshold for spreading depression,23 possibly implicating Mapt in SUDEP mechanisms. Nevertheless, our results provide the first indication that targeting Tau will not provide general protection against premature lethality among all genetic channelopathies, which may require development of gene‐specific therapies for individual subtypes of epileptic encephalopathy.

Author Contributions

CC generated the Scn1b mouse line, supervised breeding, and developed genotyping assays. CA and JKH monitored mouse survival, analyzed data, and prepared figures for Scn1b mice. RB‐S carried out crosses, monitored survival, analyzed data, and prepared figures for Scn8a mice. LLI, JLN, and MHM oversaw the experiments and wrote the manuscript.

Conflicts of Interest

None.
  26 in total

Review 1.  Sodium channel β subunits: emerging targets in channelopathies.

Authors:  Heather A O'Malley; Lori L Isom
Journal:  Annu Rev Physiol       Date:  2015       Impact factor: 19.318

2.  Sodium channel Scn1b null mice exhibit prolonged QT and RR intervals.

Authors:  Luis F Lopez-Santiago; Laurence S Meadows; Sara J Ernst; Chunling Chen; Jyoti Dhar Malhotra; Dyke P McEwen; Audrey Speelman; Jeffrey L Noebels; Sebastian K G Maier; Anatoli N Lopatin; Lori L Isom
Journal:  J Mol Cell Cardiol       Date:  2007-08-10       Impact factor: 5.000

3.  Cardiac arrhythmia in a mouse model of sodium channel SCN8A epileptic encephalopathy.

Authors:  Chad R Frasier; Jacy L Wagnon; Yangyang Oliver Bao; Luke G McVeigh; Luis F Lopez-Santiago; Miriam H Meisler; Lori L Isom
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-26       Impact factor: 11.205

Review 4.  Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms.

Authors:  Rainer Surges; Roland D Thijs; Hanno L Tan; Josemir W Sander
Journal:  Nat Rev Neurol       Date:  2009-08-11       Impact factor: 42.937

5.  Altered gene expression profile in a mouse model of SCN8A encephalopathy.

Authors:  Ryan S Sprissler; Jacy L Wagnon; Rosie K Bunton-Stasyshyn; Miriam H Meisler; Michael F Hammer
Journal:  Exp Neurol       Date:  2016-11-09       Impact factor: 5.330

6.  Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy.

Authors:  Frank H Yu; Massimo Mantegazza; Ruth E Westenbroek; Carol A Robbins; Franck Kalume; Kimberly A Burton; William J Spain; G Stanley McKnight; Todd Scheuer; William A Catterall
Journal:  Nat Neurosci       Date:  2006-08-20       Impact factor: 24.884

7.  Scn1b deletion leads to increased tetrodotoxin-sensitive sodium current, altered intracellular calcium homeostasis and arrhythmias in murine hearts.

Authors:  Xianming Lin; Heather O'Malley; Chunling Chen; David Auerbach; Monique Foster; Akshay Shekhar; Mingliang Zhang; William Coetzee; José Jalife; Glenn I Fishman; Lori Isom; Mario Delmar
Journal:  J Physiol       Date:  2014-09-17       Impact factor: 5.182

8.  Sodium channel beta1 regulatory subunit deficiency reduces pancreatic islet glucose-stimulated insulin and glucagon secretion.

Authors:  Sara J Ernst; Lydia Aguilar-Bryan; Jeffrey L Noebels
Journal:  Endocrinology       Date:  2008-11-06       Impact factor: 4.736

9.  A functional null mutation of SCN1B in a patient with Dravet syndrome.

Authors:  Gustavo A Patino; Lieve R F Claes; Luis F Lopez-Santiago; Emily A Slat; Raja S R Dondeti; Chunling Chen; Heather A O'Malley; Charles B B Gray; Haruko Miyazaki; Nobuyuki Nukina; Fumitaka Oyama; Peter De Jonghe; Lori L Isom
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

10.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice.

Authors:  H N Dawson; A Ferreira; M V Eyster; N Ghoshal; L I Binder; M P Vitek
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

View more
  1 in total

1.  Excitatory and inhibitory neuron defects in a mouse model of Scn1b-linked EIEE52.

Authors:  Jacob M Hull; Heather A O'Malley; Chunling Chen; Yukun Yuan; Nicholas Denomme; Alexandra A Bouza; Charles Anumonwo; Luis F Lopez-Santiago; Lori L Isom
Journal:  Ann Clin Transl Neurol       Date:  2020-09-26       Impact factor: 4.511

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.